Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and ...
The Herald-Mail

Cancer Survivor Doctor Invents Myofascial Release tools Used by Therapists Worldwide for Chronic Pain Relief

A research-supported myofascial release system developed from Dr. Jacobs’ clinical practice and personal healing journey Used by physical therapists, chiropractors, massage therapists, medical doctors ...
Nature

Minimized Medial Soft Tissue Release with Bone-Recut Adjustment Improves Short-Term Outcomes: Compared with Medial Release in Posterior-Stabilized Total Knee Arthroplasty.

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Targeted Oncology

FDA Grants Orphan Drug Designation to Eftilagimod Alfa for Soft Tissue Sarcoma

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...